Source: MS Trust
Initial results for two treatments in development for relapsing remitting MS, laquinimod and ponesimod, have just been released.
Laquinimod affects the levels of certain cytokines (substances released by immune cells) and reduces the passage of immune cells into the brain and spinal cord. Laboratory studies suggest it may have both neuroprotective and anti-inflammatory actions. Read full story here.